Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Cash from Operations (2020 - 2025)

Insight Molecular Diagnostics' Cash from Operations history spans 6 years, with the latest figure at 4502000.0 for Q3 2025.

  • For Q3 2025, Cash from Operations rose 18.59% year-over-year to 4502000.0; the TTM value through Sep 2025 reached 22014000.0, down 11.4%, while the annual FY2024 figure was 20713000.0, 11.2% up from the prior year.
  • Cash from Operations for Q3 2025 was 4502000.0 at Insight Molecular Diagnostics, up from 6279000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 3769000.0 in Q3 2023 and bottomed at 13277000.0 in Q1 2022.
  • The 5-year median for Cash from Operations is 6832000.0 (2023), against an average of 7483473.68.
  • The largest annual shift saw Cash from Operations crashed 82.9% in 2021 before it skyrocketed 66.93% in 2023.
  • A 5-year view of Cash from Operations shows it stood at 7065000.0 in 2021, then crashed by 36.56% to 9648000.0 in 2022, then surged by 54.15% to 4424000.0 in 2023, then dropped by 21.5% to 5375000.0 in 2024, then rose by 16.24% to 4502000.0 in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Cash from Operations are 4502000.0 (Q3 2025), 6279000.0 (Q2 2025), and 5858000.0 (Q1 2025).